Zhejiang Heze Pharmaceutical Technology Co., Ltd.

Main study purpose: To study the pharmacokinetics of the test preparation HZ005 orodispersible film and the reference preparation memantine hydrochloride oral solution in healthy adult subjects in the fasting and fed state, to compare the differences in pharmacokinetics between the test preparation and the reference preparation, and to calculate the main pharmacokinetic parameters (Cmax, AUC0-72h) and make preliminary comparisons. Secondary study purpose: To evaluate the safety of the test preparation and the reference preparation after a single oral administration in healthy subjects in the fasting and fed state.

The relative bioavailability of a single oral dose of the test preparation valsartan levoamlodipine tablets (specification: 80 mg/2.5 mg) and the reference preparations valsartan tablets (DIOVAN®, specification: 80 mg) and amlodipine besylate tablets (Norvasc®, specification: 5 mg) in healthy Chinese subjects under fasting conditions was studied, the pharmacokinetic parameters of the two preparations were analyzed, and the bioequivalence of the two preparations taken orally under fasting conditions was evaluated, so as to provide a reference for the application and clinical use of the drug.

To evaluate the effectiveness of valsartan-amlodipine tablets (specification: 80mg/2.5mg) in the treatment of mild to moderate essential hypertension by 24-hour ambulatory blood pressure monitoring (ABPM); To evaluate the safety of valsartan-amlodipine tablets (specification: 80mg/2.5mg) in the treatment of mild to moderate essential hypertension by 24-hour ambulatory blood pressure monitoring (ABPM).